Frontiers in Cardiovascular Medicine最新文献

Background: Cardiac arrest (CA) triggers a systemic inflammatory response, resulting in brain and cardiovascular dysfunction. The red blood cell distribution width (RDW)-to-albumin ratio (RAR) has been widely explored in various inflammation-related diseases. However, the predictive value of RAR for the prognosis of CA remains unclear. We aimed to explore the correlation between the RAR index and the 30- and 180-day mortality risks in post-CA patients.

Methods: Clinical data were extracted from the MIMIC-IV database. The enrolled patients were divided into three tertiles based on their RAR levels (<3.7, 3.7-4.5, >4.5). Restricted cubic spline, Kaplan-Meier (K-M) survival curves, and Cox proportional hazards regression model were used to explicate the relationship between the RAR index and all-cause mortality risk. Subgroup analyses were also conducted to increase stability and reliability. The receiver operator characteristic (ROC) analysis was used to assess the predictive ability of the RAR index, red blood cell distribution width, and serum albumin for 180-day all-cause mortality.

Results: A total of 612 patients were eligible, including 390 men, with a mean age of 64.1 years. A non-linear relationship was observed between the RAR index and 180-day all-cause mortality, with a hazards ratio (HR) >1 when the RAR level exceeded 4.54. The K-M survival curve preliminarily indicated that patients in higher tertiles (T2 and T3) of the RAR index presented lower 30- and 180-day survival rates. An elevated RAR index was significantly associated with an increased 30-day [adjusted HR: 1.08, 95% confidence interval (CI): 1.01-1.15] and 180-day (adjusted HR: 1.09, 95% CI: 1.03-1.16) mortality risk. According to the ROC curve analysis, the RAR index outperformed the RDW and albumin in predicting all-cause 180-day mortality [0.6404 (0.5958-0.6850) vs. 0.6226 (0.5774-0.6679) vs. 0.3841 (0.3390-0.4291)]. The prognostic value of the RAR index for 180-day mortality was consistent across subgroups, and a significant interaction was observed in patients who were white, those with chronic pulmonary disease, or those without cerebrovascular disease.

Conclusion: The RAR index is an independent risk factor for 30- and 180-day all-cause mortality in post-CA patients. The higher the RAR index, the higher the mortality. An elevated RAR index may be positively associated with adverse prognosis in post-CA patients, which can remind clinicians to quickly assess these patients.

Background: Chronic coronary syndromes (CCS) is a common clinical condition that increases the risk of cardiovascular events at any time. Tongxinluo capsules (TXL) are widely used in China for treating CCS.

Objectives: To systematically evaluate the therapeutic effects and safety of adding TXL to Western medical treatment (WM) for CCS.

Methods: We searched PubMed, Cochrane Library, CNKI, VIP, and Wanfang databases up to August 2024 for randomized controlled trials (RCTs) investigating the therapeutic effects and safety of combining TXL with WM compared to WM alone for CCS. Data analyses were conducted using RevMan 5.4 software.

Results: Twenty studies involving 2091 participants were identified. Evidence supports the use of TXL plus WM for reducing angina frequency [SMD -2.50, 95% CI (-3.53, -1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD -1.63, 95% CI (-2.26, -1.00)], and shortening angina duration [MD -1.50 min/once, 95% CI (-1.98, -1.02)]. Adding TXL to WM showed a non-significant trend toward reducing myocardial infarction [RR 0.34, 95% CI (0.05, 2.12); NNT = 41] and sudden cardiac death [RR 0.34, 95% CI (0.01, 8.28); NNT = 65]. No increase in adverse events was observed when TXL was added to WM [RR 1.02, 95% CI (0.70, 1.49); NNT = 149].

Conclusions: Our review suggests that TXL may offer additional therapeutic benefits for CCS patients and appears to be safe when combined with WM. Further investigations are warranted to confirm the potential impact of adding TXL to WM for CCS.

Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024499031, PROSPERO (CRD42024499031).

Obesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic cardiovascular disease, which is the leading cause of death worldwide. Bile acids (BAs) and incretins are gut hormones involved in digestion and absorption of fatty acids, and insulin secretion, respectively. In recent years BAs and incretins are increasingly recognized as key signaling molecules, which target multiple tissues and organs, beyond the gastro-intestinal system. Moreover, incretin-based therapy has revolutionized the treatment of T2DM and obesity. This mini review highlights the current knowledge about dysregulations in BA homeostasis in obesity with a special focus on atherosclerosis as well as athero-modulating roles of incretins and currently available incretin-based therapies.

Introduction: Vericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.

Material and methods: This cross-sectional, prospective and multicenter registry (VERISEC) included 776 patients from 43 centres in Spain between December 2022 and October 2023. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7) years. Patients in VERISEC were older and had more comorbidities (diabetes, advanced chronic kidney disease) compared to VICTORIA, with 20% having an estimated glomerular filtration rate below 30 ml/min. They also had higher natriuretic peptide levels [NT-proBNP: 3551 (IQR: 1,675.9, 7,054.0)] pg/ml. Most patients (79.8%) started vericiguat after HF decompensation within the previous three months, with high use of loop diuretics (with an average dose of 65 mg/day) and implanted devices (50%). Sixty percent of patients were on quadruple therapy, with a higher use of sodium-glucose co-transporter 2 inhibitors compared to the VICTORIA trial. Despite the more severe disease in the VERISEC cohort, the implementation of guideline-directed medical therapy was greater than in VICTORIA, although vericiguat was initiated at lower blood pressure levels.

Conclusions: Patients in the VERISEC registry had more severe illness and higher comorbidities compared to those in the VICTORIA, despite receiving optimised treatments. Further research is needed to identify which patients may benefit the most from vericiguat treatment.

Background: Few studies have examined the relationship between nutritional status, as assessed by the Prognostic Nutrition Index (PNI), and incident cardiovascular mortality and all-cause mortality, particularly in hypertensive patients. This study aimed to examine the association between PNI and cardiovascular mortality and all-cause mortality in Americans with hypertension.

Methods: Data from this retrospective cohort study were obtained from the National Health and Nutrition Examination (NHANES) 1999-2016. Using data of The NHANES Public-Use Linked Mortality Files to assess all-cause mortality (ACM) and cardiovascular mortality (CVM). After excluding participants younger than 18 years, without hypertension, and with missing follow-up data, a total of 18,189 cases were included in this study. Persons with hypertension were divided by PNI into 4 groups: Q1 (PNI < 49.0), Q2 (PNI: 49.0-52.5), Q3 (PNI: 52.5-55.5), and Q4 (PNI > 55.5). We used the Cox proportional hazard regression model to explore the predictive role of PNI on ACM and CVM in American adults with hypertension. Restricted cubic spline (RCS) curves to investigate the existence of a dose-response linear relationship between them.

Result: During a median follow-up period of 89 months, a total of 1,444 (7.94%) cardiovascular deaths occurred and 5,171 (28.43%) all-cause deaths occurred. Multifactorial COX regression analysis showed all-cause mortality [hazard ratio (HR): 0.584, 95% CI: 0.523-0.652, p < 0.001] and cardiovascular mortality (HR: 0.435, 95% CI: 0.349-0.541, p < 0.001) associated with Q4 group risk of malnutrition in PNI compared to Q1 group. RCS curves showed a nonlinear relationship between PNI and all-cause mortality and cardiovascular mortality (both non-linear p < 0.001).

Conclusions: Lower PNI levels are associated with mortality in patients with hypertension. PNI may be a predictor of all-cause mortality and cardiovascular mortality risk in patients with hypertension.

Background: The relationship between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and telomere length (TL) remains unclear. This study aims to investigate their association in a nationally representative US population.

Methods: Data from 6,342 adults aged ≥20 were obtained from the National Health and Nutrition Examination Survey (NHANES) 1999-2002. The NHHR was calculated and categorized into tertiles. TL was measured as the telomere-to-standard reference DNA ratio. Multivariate linear regression and smooth curve fitting were employed to assess the association between NHHR and TL.

Results: The study population (mean age 45.1 ± 0.4 years, 48.9% male) was stratified into NHHR tertiles. Compared with the lowest NHHR tertile, the highest NHHR tertile was associated with adverse inflammatory and cardiometabolic profiles, including elevated white blood cell counts (6.88 ± 0.07-7.54 ± 0.08 × 10⁹/L) and increased prevalence of hypertension (18.81%-25.71%) and diabetes (3.38%-7.17%). An elevated NHHR was significantly associated with a shorter TL (T/S ratio: 1.09 ± 0.02-1.03 ± 0.02; P = 0.0005). This association remained significant in partially adjusted models but was attenuated in a fully adjusted model. Significant interactions were observed for age and hypertension status.

Conclusion: This study revealed a linear inverse association between NHHR and TL, suggesting the utility of the NHHR as a novel biomarker for biological aging. Further prospective studies are warranted to validate these findings.

Objective: To investigate the effects of dapagliflozin, in addition to standard therapy, on heart rate variability (HRV), soluble growth stimulation expressed gene 2 protein (sST2), N-terminal pro B-type natriuretic peptide (NT-proBNP), and echocardiographic parameters in patients with early-onset post-myocardial infarction heart failure (HF).

Methods: A total of 98 patients with early-onset post-myocardial infarction HF were enrolled and randomly divided into a control group (n = 48, receiving standard therapy) and an observation group (n = 50, receiving standard therapy plus dapagliflozin 10 mg daily). HRV, cardiac function, and echocardiographic parameters were measured at baseline and after 24 weeks of treatment. Short-term prognosis and adverse events were also monitored.

Results: Compared with the control group, the observation group showed significantly greater improvements in SDNN and SDANN (P < 0.05). Significant improvements were also observed in sST2 and NT-proBNP levels in the observation group compared to the control group (P < 0.05). Additionally, echocardiographic parameters, including EF, LVESD, LVEDD, IVST, LVMI, and E/e', showed greater improvement in the observation group (P < 0.05). The incidence of major adverse cardiovascular events was lower in the observation group (P < 0.05). Multivariate logistic regression model revealed that dapagliflozin use was independently associated with a reduced risk of MACE (OR = 0.265, 95% CI: 0.097-0.724, P = 0.010).

Conclusion: Early administration of dapagliflozin 10 mg, in addition to standard therapy, can improve autonomic function, cardiac function, and short-term prognosis in patients with early-onset post-myocardial infarction heart failure.

This review addresses the correlation between arterial stiffness, measured by pulse wave velocity (PWV), and retinal microvascular changes, highlighting the retina as an important accessible window for inferences about cardiovascular health. Arterial stiffness, intrinsically linked to vascular aging and several comorbidities, results in damage to the microcirculation, including ocular vasculature, which can act as a predictor of cardiovascular and cerebrovascular outcomes. The review highlights the relationship between PWV assessment and funduscopic examination, with the aim of improving diagnostic accuracy and optimizing the clinical application of these tools in the management of cardiovascular and ophthalmological diseases, thus promoting more effective and early intervention.

Introduction: The risk of mortality associated with cardiac arrhythmias is considerable, and their diagnosis presents significant challenges, often resulting in misdiagnosis. This situation highlights the necessity for an automated, efficient, and real-time detection method aimed at enhancing diagnostic accuracy and improving patient outcomes.

Methods: The present study is centered on the development of a portable deep learning model for the detection of arrhythmias via electrocardiogram (ECG) signals, referred to as CardioAttentionNet (CANet). CANet integrates Bi-directional Long Short-Term Memory (BiLSTM) networks, Multi-head Attention mechanisms, and Depthwise Separable Convolution, thereby facilitating its application in portable devices for early diagnosis. The architecture of CANet allows for effective processing of extended ECG patterns and detailed feature extraction without a substantial increase in model size.

Results: Empirical results indicate that CANet outperformed traditional models in terms of predictive performance and stability, as confirmed by comprehensive cross-validation. The model demonstrated exceptional capabilities in detecting cardiac arrhythmias, surpassing existing models in both cross-validation and external testing scenarios. Specifically, CANet achieved high accuracy in classifying various arrhythmic events, with the following accuracies reported for different categories: Normal (97.37 ± 0.30%), Supraventricular (98.09 ± 0.25%), Ventricular (92.92 ± 0.09%), Atrial Fibrillation (99.07 ± 0.13%), and Unclassified arrhythmias (99.68 ± 0.06%). In external evaluations, CANet attained an average accuracy of 94.41%, with the area under the curve (AUC) for each category exceeding 99%, thereby demonstrating its substantial clinical applicability and significant advancements over traditional models.

Discussion: The deep learning model proposed in this study has the potential to enhance the accuracy of early diagnosis for various types of arrhythmias. Looking ahead, this technology is anticipated to provide improved medical services for patients with heart disease through continuous, non-invasive monitoring and timely intervention.

Objective: Interstage home monitoring (IHM) programs are considered standard of care after Norwood palliation and have led to substantial improvements in clinical outcomes. This study aims to evaluate an application-based remote IHM program for infants with shunt- or duct-dependent pulmonary circulation. The primary goals were to discharge infants from the hospital while minimizing mortality, optimizing somatic growth, and enhancing caregivers' confidence in the clinical management at home.

Methods: Infants with shunt-dependent single ventricle physiology or complex biventricular physiology requiring staged palliation with aortopulmonary shunt were enrolled for the study. Caregivers completed a comprehensive education program on the clinical management of their child at home and were asked to remotely send monitoring data using an application. We analyzed demographic data and clinical outcomes; evaluated patient acceptance and adherence, as well as data entry patterns and metrics; and compared these to a historical control group monitored in a non-remote IHM program and with a propensity score-matched cohort adjusted for baseline characteristics.

Results: We enrolled 30 infants in the remote IHM program between July 2021 and May 2024. The median duration of IHM was 110 days (IQR 75-140). A median of 353 (IQR 351-743) data entries were sent per patient during IHM of which 0.8% (IQR 0.3-1.9) were pathological. Readmissions (63%) and interventions (57%) were common, mainly due to cyanosis and infections. As all infants survived stage II palliation, interstage mortality could be reduced to 0% compared to 10.3% in the historical control group and was significantly lower compared to the propensity score-matched cohort with 14% (P = 0.032).

Conclusion: Application-based remote IHM for infants with duct- or shunt-dependent pulmonary perfusion is feasible, with high acceptance and adherence. The program significantly reduced interstage mortality compared to traditional monitoring methods. Remote patient monitoring (RPM) improves communication between caregivers and healthcare teams, allowing for early intervention and optimized patient outcomes. RPM has the potential to improve outcomes, enhance patient safety, and reduce family burden in this high-risk population.